A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

Summary

The purpose of this study is to compare duloxetine with other antidepressants in the treatment of severe depression.

Timeline

Start

2008-05

Primary completion

2009-02

Completion

2009-03

Outcome

Missed primary endpoint

paper The primary outcome, remission at week 12 by QIDS-SR, was numerically greater for duloxetine compared with SSRIs (36 vs. 32%), but this difference was not statistically significant. PMID 22027844 ↗

paper Remission superiority on the QIDS-SR was not achieved. PMID 22027844 ↗

Publications

• Dodd S, Berk M, Kelin K, Zhang Q, Eriksson E, Deberdt W, Craig Nelson J. Application of the Gradient Boosted method in randomised clinical trials: Participant variables that contribute to depression treatment efficacy of duloxetine, SSRIs or placebo. J Affect Disord. 2014 Oct;168:284-93. doi: 10.1016/j.jad.2014.05.014. Epub 2014 Jun 4.
• Martinez JM, Katon W, Greist JH, Kroenke K, Thase ME, Meyers AL, Edwards SE, Marangell LB, Shoemaker S, Swindle R. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin Psychopharmacol. 2012 Jan;27(1):17-26. doi: 10.1097/YIC.0b013e32834ce11b.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Citalopram	Small molecule	20 mg	Oral
Comparator	Citalopram	Small molecule	40 mg	Oral
Subject	Duloxetine	Small molecule	30 mg	Oral
Subject	Duloxetine	Small molecule	120 mg	Oral
Comparator	Fluoxetine	Small molecule	20 mg	Oral
Comparator	Fluoxetine	Small molecule	80 mg	Oral
Comparator	Paroxetine	Small molecule	20 mg	Oral
Comparator	Paroxetine	Small molecule	50 mg	Oral
Comparator	Sertraline	Small molecule	50 mg	Oral
Comparator	Sertraline	Small molecule	200 mg	Oral

Indications